Literature DB >> 27095813

Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system.

Ujjawal Roy1, Urmila Das1, Alak Pandit1, Anjan Debnath1.   

Abstract

Sjögren-Larsson syndrome is a recessively inherited disease caused by a deficiency of fatty aldehyde dehydrogenase with presenting features of congenital ichthyosis, spastic diplegia or tetraplegia, and mental retardation. The basic pathogenic mechanism is deficiency of fatty aldehyde dehydrogenase, which may lead to an accumulation of long-chain fatty alcohols hampering cell membrane integrity, which further disrupts the barrier function of skin and white matter of the brain. MRI of the brain shows diffuse symmetrical white matter hyperintensities on T2-weighted sequences. Although there is no definitive cure for Sjögren-Larsson syndrome, most patients survive until adulthood and management involves therapies directed towards controlling specific problems. We present a case of Sjögren-Larsson syndrome with classical clinical and MRI features, including a few distinctly atypical characteristics in various attributes. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27095813      PMCID: PMC4840703          DOI: 10.1136/bcr-2016-215110

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Sjögren-Larsson syndrome: explaining the skin-brain connection.

Authors:  W B Rizzo
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

2.  Dystonia secondary to Sjögren-Larsson syndrome.

Authors:  E Cubo; C G Goetz
Journal:  Neurology       Date:  2000-10-24       Impact factor: 9.910

3.  Sjögren-Larsson syndrome: clinical and MRI/MRS findings in FALDH-deficient patients.

Authors:  P H van Domburg; M A Willemsen; J J Rotteveel; J G de Jong; H O Thijssen; A Heerschap; J R Cruysberg; R J Wanders; F J Gabreëls; P M Steijlen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

Review 4.  Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome.

Authors:  M A Willemsen; L IJlst; P M Steijlen; J J Rotteveel; J G de Jong; P H van Domburg; E Mayatepek; F J Gabreëls; R J Wanders
Journal:  Brain       Date:  2001-07       Impact factor: 13.501

5.  Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts.

Authors:  W B Rizzo; D A Craft
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

6.  Sjögren-Larsson syndrome: physical and neurological features. A survey of 35 patients.

Authors:  S Jagell; J Heijbel
Journal:  Helv Paediatr Acta       Date:  1982

7.  Sjögren-Larsson syndrome in Sweden. A clinical, genetic and epidemiological study.

Authors:  S Jagell; K H Gustavson; G Holmgren
Journal:  Clin Genet       Date:  1981-04       Impact factor: 4.438

8.  MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy.

Authors:  Michèl A A P Willemsen; Marinette Van Der Graaf; Marjo S Van Der Knaap; Arend Heerschap; Peter H M F Van Domburg; Fons J M Gabreëls; Jan J Rotteveel
Journal:  AJNR Am J Neuroradiol       Date:  2004-04       Impact factor: 3.825

Review 9.  Sjögren-Larsson syndrome in clinical practice.

Authors:  Joris Fuijkschot; Thomas Theelen; Marieke M B Seyger; Marinette van der Graaf; Imelda J M de Groot; Ron A Wevers; Ronald J A Wanders; Hans R Waterham; Michèl A A P Willemsen
Journal:  J Inherit Metab Dis       Date:  2012-07-26       Impact factor: 4.982

10.  Specific changes in the fundus typical for the Sjögren-Larsson syndrome. An ophthalmological study of 35 patients.

Authors:  S Jagell; W Polland; O Sandgren
Journal:  Acta Ophthalmol (Copenh)       Date:  1980-06
View more
  1 in total

1.  Uncrossed corticospinal tracts in a patient with ichthyosis and hemiparesis: a case report.

Authors:  Huijia Yang; Hongwei Zhou; Jing Miao
Journal:  BMC Neurol       Date:  2020-04-06       Impact factor: 2.474

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.